Gefitinib plus Fuzheng Kang'ai Formula (扶正抗癌方) in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutation: a …
X Yang, X Chai, W Wu, S Long, H Deng, Z Pan… - Chinese journal of …, 2018 - Springer
… (3) Gefitinib and erlotinib are the first small molecule tyrosine … , squamouscell carcinoma or
adeno-squamous carcinoma, were … with EGFRTKI resistant NSCLC, afatinib is one of the most …
adeno-squamous carcinoma, were … with EGFRTKI resistant NSCLC, afatinib is one of the most …
阿法替尼用于晚期肺鳞癌二线治疗——LUX-Lung 8 研究深度解读
梁颖 - 循证医学, 2015 - jebm.cn
… Afatinib versus Erlotinib as second⁃line treatment of patients with advanced squamous
cell carcinoma of the lung(LUX⁃Lung 8):An open⁃label randomised controlled phase 3 trial[J]. …
cell carcinoma of the lung(LUX⁃Lung 8):An open⁃label randomised controlled phase 3 trial[J]. …
厄洛替尼治疗携带EGFR A289V 突变的晚期非小细胞肺鳞癌患者1 例并文献复习
祝冰晶， 钱娟娟， 李敬杰， 蔡诗雨， 唐春兰 - 肿瘤综合治疗电子杂志, 2020 - jmcm2018.com
… 细胞肺癌(non-small cell lung cancer,NSCLC)和小细胞肺癌(small cell lung cancer,SCLC),NSCLC约
占… Afatinib and Erlotinib in the treatment of squamous-cell lung cancer[J]. Expert Opin …
占… Afatinib and Erlotinib in the treatment of squamous-cell lung cancer[J]. Expert Opin …
驱动基因阳性肺鳞癌的疗效及肿瘤免疫微环境探索分析
高青云， 林晓程， 陈雨晴， 高玲玲， 李余发， 郑明英… - 循证医学, 2022 - jebm.cn
… squamous cell lung carcinoma(SqCLC)patients. This study aimed to analyze the mutation
status and the efficacy of different treatment … P13 received afatinib but the PFS was only 0.7 m,…
status and the efficacy of different treatment … P13 received afatinib but the PFS was only 0.7 m,…
[PDF][PDF] 晚期非小细胞肺癌靶向治疗的研究进展
姜文丽， 黄才国 - 药学实践杂志, 2016 - yxsj.smmu.edu.cn
… represented by Gefitinib ,Erlotinib ,Afatinib and an唱 … Management of advanced non唱small
cell lung cancers with known mutations or rear唱 rangements :Latest evidence and treatment …
cell lung cancers with known mutations or rear唱 rangements :Latest evidence and treatment …
[HTML][HTML] Pan-negative 型非小细胞肺癌的研究进展
孙丽， 熊志成， 韩琤波 - Chinese Journal of Lung Cancer, 2018 - ncbi.nlm.nih.gov
… -cell lung cancer previously treated with platinum-containing chemotherapy regimens.
The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18(12):2354–2362. …
The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18(12):2354–2362. …
利用新一代EGFR 酪氨酸激酶抑制劑為放射增敏劑, 用於膀胱癌的治療
蔡育傑 - 2015 - tdr.lib.ntu.edu.tw
… of afatinib on protein phosphorylations in lung cancer cells.....… In contrast, the squamous cell
cancer-like subtype uniformly … irradiation (compared with afatinib or erlotinib treatment alone) …
cancer-like subtype uniformly … irradiation (compared with afatinib or erlotinib treatment alone) …
Erlotinib 用於肺腺癌EGFR 野生型患者化學治療後之療效探討
劉錦鳳， 鄭幸宜， 李樂業 - 臺灣臨床藥學雜誌, 2018 - airitilibrary.com
… 的型態可以 分為鱗狀細胞癌(squamous cell carcinoma), 腺癌(… ,在使用EGFR-TKIs (gefitinib/erlotinib/
afatinib) 時,比EGFR 基因… Maintenance erlotinib in advanced nonsmall cell lung cancer…
afatinib) 時,比EGFR 基因… Maintenance erlotinib in advanced nonsmall cell lung cancer…
[HTML][HTML] 驱动基因阳性肺腺癌在靶向治疗中病理类型转化的机制与治疗策略
谢同济， 李研， 邢镨元 - Chinese Journal of Lung Cancer, 2020 - ncbi.nlm.nih.gov
… Histological transformation includes the transformation from lung ADC to small cell lung
cancer (SCLC), squamous cell carcinoma (SCC), and large cell neuroendocrine carcinoma (…
cancer (SCLC), squamous cell carcinoma (SCC), and large cell neuroendocrine carcinoma (…